HK1008741A1 - Indoline derivatives carrying an amide function their preparation and pharmaceutical compositions containing them - Google Patents

Indoline derivatives carrying an amide function their preparation and pharmaceutical compositions containing them

Info

Publication number
HK1008741A1
HK1008741A1 HK98108861A HK98108861A HK1008741A1 HK 1008741 A1 HK1008741 A1 HK 1008741A1 HK 98108861 A HK98108861 A HK 98108861A HK 98108861 A HK98108861 A HK 98108861A HK 1008741 A1 HK1008741 A1 HK 1008741A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
mono
substd
halogen
opt
Prior art date
Application number
HK98108861A
Inventor
Jean Wagnon
Claudine Serradeil-Ilegal
Bernard Tonnerre
Claude Plouzane
Dino Nisato
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HK1008741A1 publication Critical patent/HK1008741A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

3-Hydroxy-1-indolinyl sulphones of formula (I) and their salts are new: In (I), R1 = halogen, 1-4C alkyl, OH, 1-4C alkoxy, benzyloxy, CN, CF3, NO2 or NH2; R2 = 1-6C alkyl; 3-7C cycloalkyl,; 5-7C cycloalkenyl; phenyl opt. substd. by 1-4C alkyl, 1-4C alkoxy, halogen, CF3 and/or NH2; or nitrophenyl opt. substd. by CF3, 1-4C alkyl or halogen; R5 = 1-4C alkyl; 1- or 2-naphthyl;5-dimethylamino-1-naphthyl; phenyl opt. substd. by halogen, CF3, NH2, mono- or di (1-4C alkyl) amino, OH, 1-4C alkoxy, 2-4C alkenyloxy, 1-4C alkylthio, CF3, benzyloxy, CN, COOH, 2-5C alkoxycarbonyl, CONH2, mono- or di (1-4C alkyl)carbamoyl or 1-4C alkanoylamino; or nitrophenyl opt. substd. by CF3, 2-4C alkenyloxy, halogen, 1-4C alkyl, 1-4C alkoxy, 1-4C alkylthio, OCF3 or benzyloxy; R6 = 1-6C alkyl or R7; R7 = 1-R-4-piperidinyl, 1-R-3-azetidinyl or (CH2)rR'; R = H, 1-4C alkyl, benzyloxycarbonyl or 2-5C alkoxycarbonyl; R1 = pyridyl, OH, NH2, mono- or di(1-4C alkyl)amino, COOH, 2-5C alkoxycarbonyl, benzylcarbonyl, CONH2 or mono- or di(1-4C alkyl)carbamoyl; or NR6R7 = morpholino; thiomorpholino; thiazolidinyl or 2,2-dimethylthiazolidinyl opt. substd. by R8; 1-piperazinyl opt. 4-substd. by R"8; and unsatd. 5-membered monoaza ring substd. by R8; or a satd. 3- to 7-membered monoaza ring substd. by R8 and R9; R8 = R'8 or (CH2)rA1, where A1 = OH, NH2 or mono- or di(1-4C alkyl)amino; R'8 = (CH2)qA2, where A2 = COOH, 2-5C alkoxycarbonyl, benzyloxycarbonyl, CONH2, CONHOH, mono- or di(1-4C alkyl)carbamoyl, CSNH2 or mono- or di(1-4C alkyl)thiocarbamoyl; R"8 = R8' or (CH2)A3, where A3 = NH2 or mono- or di(1-4C alkyl)amino; R9 = H, halogen, (CH2rOR10), (CH2)rNR11R12, (CH2)SCONR11R'11 or N3; R10 = H, 1-4C alkyl, mesyl or tosyl; R11, R'11 and R12 = H or 1-4C alkyl, or R11 = H, and R12 = benzyloxycarbonyl or 2-5C alkoxycarbonyl; n and m = 0-2; q = 0-3; r = 0-3, but not 0 when R8 or R9 is in a position alpha to the intracyclic amidic nitrogen (SiC); s = 0 or 1.
HK98108861A 1991-08-02 1998-07-03 Indoline derivatives carrying an amide function their preparation and pharmaceutical compositions containing them HK1008741A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9109908A FR2679903B1 (en) 1991-08-02 1991-08-02 DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.

Publications (1)

Publication Number Publication Date
HK1008741A1 true HK1008741A1 (en) 1999-05-14

Family

ID=9415909

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98108861A HK1008741A1 (en) 1991-08-02 1998-07-03 Indoline derivatives carrying an amide function their preparation and pharmaceutical compositions containing them

Country Status (29)

Country Link
EP (1) EP0526348B1 (en)
JP (1) JP2633085B2 (en)
KR (1) KR100241583B1 (en)
AT (1) ATE163289T1 (en)
AU (2) AU658664B2 (en)
BR (1) BR9205336A (en)
CA (2) CA2093221C (en)
CZ (1) CZ288173B6 (en)
DE (1) DE69224450T2 (en)
DK (1) DK0526348T3 (en)
ES (1) ES2117038T3 (en)
FI (2) FI104069B (en)
FR (1) FR2679903B1 (en)
HK (1) HK1008741A1 (en)
HU (2) HUT68927A (en)
IL (3) IL102703A (en)
LT (1) LT3064B (en)
LV (1) LV10091B (en)
MX (1) MX9204487A (en)
MY (1) MY110517A (en)
NO (1) NO180047C (en)
NZ (1) NZ243795A (en)
PH (1) PH30661A (en)
RU (1) RU2104268C1 (en)
SG (1) SG47501A1 (en)
SK (1) SK283463B6 (en)
UA (1) UA27238C2 (en)
WO (1) WO1993003013A1 (en)
ZA (1) ZA925781B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665441B1 (en) * 1990-07-31 1992-12-04 Sanofi Sa N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
FR2708608B1 (en) * 1993-07-30 1995-10-27 Sanofi Sa N-sulfonylbenzimidazolone derivatives, their preparation, pharmaceutical compositions containing them.
FR2756736B1 (en) * 1996-12-05 1999-03-05 Sanofi Sa PHARMACEUTICAL COMPOSITIONS CONTAINING N-SULFONYL INDOLINE DERIVATIVES
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
BR9811569A (en) * 1997-07-31 2000-09-19 Elan Pharm Inc Compounds that inhibit vla-4-mediated leukocyte adhesion
PL338373A1 (en) * 1997-07-31 2000-10-23 Elan Pharm Inc Dipeptide and its affinite compounds inhibiting adhesion of leucocytes occurring through mediation of vla-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
BR9811594A (en) * 1997-07-31 2000-09-05 Elan Pharm Inc Sulphonylated dipeptide compounds that inhibit vla-4 mediated leukocyte adhesion
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
FR2775598A1 (en) 1998-03-06 1999-09-10 Sanofi Sa PHARMACEUTICAL COMPOSITIONS COMPRISING A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V1A RECEPTORS AND A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V2 RECEPTORS
FR2778103A1 (en) * 1998-04-29 1999-11-05 Sanofi Sa PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION A V1A ARGININE-VASOPRESSIN ANTAGONIST AND AN ANGIOTENSIN II AT1 RECEPTOR ANTAGONIST
FR2786486B3 (en) * 1998-11-16 2000-12-08 Sanofi Sa PROCESS FOR THE PREPARATION OF (2S) -1 - [(2R, 3S) -5-CHLORO-3- (2- CHLOROPHENYL) -1- (3,4-DIMETHOXY BENZENESULFONYL) -3-HYDROXY- 2,3-DIHYDRO- 1H-INDOLE-2-CARBONYL] PYRROLIDINE-2-CARBOXAMIDE, ITS SOLVATES AND / OR HYDRATES
CA2359115C (en) 1999-01-22 2011-06-21 Elan Pharmaceuticals, Inc. Acyl derivatives which treat vla-4 related disorders
AR035476A1 (en) 1999-01-22 2004-06-02 Elan Pharm Inc HETEROARILO AND HETEROCICLIC COMPOUNDS WITH FUSIONED RING, WHICH INHIBIT THE ADHESION OF LEUKOCYTES THROUGH VLA-4, PHARMACEUTICAL COMPOSITIONS, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A BIOLOGICAL METHOD 4
CA2359114A1 (en) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
FR2792834A1 (en) * 1999-04-29 2000-11-03 Sanofi Sa USE OF SR 49059, ITS PHARMACEUTICALLY ACCEPTABLE SOLVATES AND / OR HYDATES FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OR PREVENTION OF RAYNAUD PHENOMENON
FR2805536B1 (en) * 2000-02-25 2002-08-23 Sanofi Synthelabo NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2805992A1 (en) * 2000-03-08 2001-09-14 Sanofi Synthelabo Oral administration of N-sulfonyl-indoline derivative to treat central nervous system, cardiovascular or gastric disorders, using polyethylene glycol, polysorbate and poloxamer as solubilizers for high bioavailability
AU1401902A (en) 2000-10-17 2002-04-29 Applied Research Systems Pharmaceutically active sulfanilide derivatives
WO2002044179A1 (en) 2000-11-28 2002-06-06 Yamanouchi Pharmaceutical Co., Ltd. 1,4,5,6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof
JP4044740B2 (en) * 2001-05-31 2008-02-06 信越化学工業株式会社 Resist material and pattern forming method
DK1458381T3 (en) 2001-12-20 2006-03-20 Applied Research Systems Triazoles as oxytocin antagonists
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
CA2498091C (en) * 2002-10-11 2011-03-22 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic acid derivatives
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
DK1940826T3 (en) 2005-09-29 2011-04-18 Elan Pharm Inc Pyrimidinylamide compounds that inhibit leukocyte adhesion mediated through BLA-4
EP1940827B1 (en) 2005-09-29 2011-03-16 Elan Pharmaceuticals Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
JP5135235B2 (en) 2006-02-27 2013-02-06 エラン ファーマシューティカルズ，インコーポレイテッド Pyrimidinylsulfonamide compounds that inhibit leukocyte adhesion mediated by VAL-4
WO2010126914A1 (en) 2009-04-27 2010-11-04 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
TW201938171A (en) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 Tricyclic compounds as vasopressin V1a receptor antagonists
HU231206B1 (en) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
US4479963A (en) * 1981-02-17 1984-10-30 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
DE3705934A1 (en) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl derivatives, processes for their preparation, and their use as medicaments
FR2665441B1 (en) * 1990-07-31 1992-12-04 Sanofi Sa N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.

Also Published As

Publication number Publication date
IL102703A0 (en) 1993-01-14
KR100241583B1 (en) 2000-03-02
UA27238C2 (en) 2000-08-15
CA2093221A1 (en) 1993-02-03
FI980175A0 (en) 1998-01-27
MY110517A (en) 1998-07-31
NO180047B (en) 1996-10-28
LV10091B (en) 1995-04-20
DK0526348T3 (en) 1998-11-23
EP0526348A1 (en) 1993-02-03
DE69224450D1 (en) 1998-03-26
CA2206776C (en) 2002-02-26
DE69224450T2 (en) 1998-07-30
NZ243795A (en) 1995-04-27
FI931476A0 (en) 1993-04-01
IL117592A (en) 1999-04-11
JP2633085B2 (en) 1997-07-23
NO180047C (en) 1997-02-05
IL102703A (en) 1997-03-18
AU2475892A (en) 1993-03-02
FI104069B1 (en) 1999-11-15
CA2093221C (en) 1998-09-22
FI104069B (en) 1999-11-15
PH30661A (en) 1997-09-16
MX9204487A (en) 1993-02-01
HU211884A9 (en) 1995-12-28
ES2117038T3 (en) 1998-08-01
FI107048B (en) 2001-05-31
SK283463B6 (en) 2003-08-05
SK42693A3 (en) 1993-10-06
IL117592A0 (en) 1996-07-23
CZ68293A3 (en) 1994-01-19
WO1993003013A1 (en) 1993-02-18
FR2679903A1 (en) 1993-02-05
LV10091A (en) 1994-05-10
CA2206776A1 (en) 1993-02-03
HUT68927A (en) 1995-08-28
RU2104268C1 (en) 1998-02-10
LT3064B (en) 1994-10-25
FR2679903B1 (en) 1993-12-03
NO931262D0 (en) 1993-04-01
NO931262L (en) 1993-05-26
CZ288173B6 (en) 2001-05-16
AU658664B2 (en) 1995-04-27
HU9300951D0 (en) 1993-06-28
JPH06501960A (en) 1994-03-03
ATE163289T1 (en) 1998-03-15
FI980175A (en) 1998-01-27
BR9205336A (en) 1993-11-16
LTIP114A (en) 1994-06-15
FI931476A (en) 1993-04-01
EP0526348B1 (en) 1998-02-18
ZA925781B (en) 1993-03-02
AU691223B2 (en) 1998-05-14
SG47501A1 (en) 1998-04-17
AU1154195A (en) 1995-05-04

Similar Documents

Publication Publication Date Title
HK1008741A1 (en) Indoline derivatives carrying an amide function their preparation and pharmaceutical compositions containing them
PT81748A (en) Process for the preparation of novel oxetanones of novel intermediates which are usable in this process and of pharmaceutical compositions based on said oxetanones or based on precursors thereof
SG49053A1 (en) Arylalkylamines process for preparing them and pharmaceutical compositions containing them
MX9603508A (en) 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics.
ES2002012A6 (en) 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof.
NZ333926A (en) Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use
ATE189459T1 (en) PEPTIDES WITH ENDOTHELIN ANTAGONISTIC ACTIVITY. THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
ES8607910A1 (en) Tertiary amines.
GB1181288A (en) Novel Pyrazinamides and their Preparation
ES8101045A1 (en) Substituted 3-(1-pyrrolidinyl)-5-sulfamoyl-benzoic acid derivatives, a process for their preparation, pharmaceutical preparations containing them and a process for the preparation thereof.
HUP9902606A2 (en) Matrix metalloproteinase inhibitors
GB1505848A (en) 3,4-dicarboxycephalosporins and derivatives
ES8404362A1 (en) 7-Hydroxy-imino-amino-thiadiazolyl -acetamido-3-cephem derivs.
NZ240398A (en) Imidazol-2-yl derivatives of substituted bicyclic compounds; medicaments,

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20040803